LifeSan Clinical Research is a full-service clinical research division of Centaur Pharmaceuticals Pvt. Ltd. LifeSan is located in Mumbai, the financial capital of India. LifeSan offers services of bioavailability-bioequivalence studies in male and female Subjects as well as late-phase [phase II, III and IV] clinical trials along with full-fledged statistical services including CDISC datasets. Since its inception in 2008, LifeSan has been successfully inspected by USFDA, EMA, MHRA, SAHPRA, ISP-Chile, NPRA and of course CDSCO, India. Additionally, studies conducted at LifeSan have also been successfully submitted to TGA [Australia], Health Canada and CIS countries.

LifeSan’s motto of “We Impart Quality to Research” speaks for the impeccable quality of operations with extreme transparency, due to which, LifeSan is the proud partner of several esteemed pharmaceutical companies for their clinical development programs.

One of major feet in LifeSan’s history is the clinical development of the New Chemical Entity [NCE] “Diperoxochloric Acid [DPOCL]” topical solution for the treatment of Diabetic Foot Ulcer, an unmet medical need. LifeSan, in collaboration with CytoTools, AG, Germany had successfully completed pre-clinical studies as well as phase II and III clinical trials across multiple sites in India. The ICMR and CDSCO formally approved “Diperoxochloric Acid [DPOCL]” topical solution in 2019 after thorough review of the data from the studies. The product is proudly marketed as “WOXheal” by the parent organization Centaur Pharmaceuticals Pvt. Ltd.

LifeSan has continued the clinical development of Diperoxochloric Acid [WOXheal] topical solution by conducting phase IV clinical trials as well as phase III clinical trials in additional indications of venous leg ulcers [VLU] and pressure ulcer [PU].